Xifeng Wu

List of Publications by Year
in descending order

400 papers	25,774 citations
6613 79 h-index	10445 139 g-index
410 all docs	410 docs citations
410 times ranked	33166 citing authors

#	Article	IF	Citations
1	A whole-exome case-control association study to characterize the contribution of rare coding variation to pancreatic cancer risk. Human Genetics and Genomics Advances, 2022, 3, 100078.	1.7	0
2	Low-Glycemic Index Diets as an Intervention in Metabolic Diseases: A Systematic Review and Meta-Analysis. Nutrients, 2022, 14, 307.	4.1	15
3	â€œSugar-Sweetened Beveragesâ€•Is an Independent Risk From Pancreatic Cancer: Based on Half a Million Asian Cohort Followed for 25 Years. Frontiers in Oncology, 2022, 12, 835901.	2.8	2
4	Predictive Utility of Mortality by Aging Measures at Different Hierarchical Levels and the Response to Modifiable Life Style Factors: Implications for Geroprotective Programs. Frontiers in Medicine, 2022, 9, 831260.	2.6	1
5	Different Transmission Dynamics of Coronavirus Disease 2019 (COVID-19) and Influenza Suggest the Relative Efficiency of Isolation/Quarantine and Social Distancing Against COVID-19 in China. Clinical Infectious Diseases, 2021, 73, e4305-e4311.	5.8	15
6	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
7	Population-based targeted sequencing of 54 candidate genes identifies *PALB2* as a susceptibility gene for high-grade serous ovarian cancer. Journal of Medical Genetics, 2021, 58, 305-313.	3.2	26
8	Circulating adipokine concentrations and risk of five obesityâ€related cancers: A Mendelian randomization study. International Journal of Cancer, 2021, 148, 1625-1636.	5.1	29
9	Integration of multiomic annotation data to prioritize and characterize inflammation and immuneâ€related risk variants in squamous cell lung cancer. Genetic Epidemiology, 2021, 45, 99-114.	1.3	7
10	Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study. Cancer Immunology, Immunotherapy, 2021, 70, 701-712.	4.2	40
11	Trend Analysis and Intervention Effect Starting Point Detection of COVID-19 Epidemics Using Recalibrated Time Series Models â€" Worldwide, 2020. China CDC Weekly, 2021, 3, 417-422.	2.3	1
12	Smoking and nasopharyngeal cancer: individual data meta-analysis of six prospective studies on 334Â935 men. International Journal of Epidemiology, 2021, 50, 975-986.	1.9	12
13	Discovery and fine-mapping of height loci via high-density imputation of GWASs in individuals of African ancestry. American Journal of Human Genetics, 2021, 108, 564-582.	6.2	18
14	Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Nature Communications, 2021, 12, 2788.	12.8	11
15	Identification of 22 susceptibility loci associated with testicular germ cell tumors. Nature Communications, 2021, 12, 4487.	12.8	27
16	Genetic determinants of multiple myeloma risk within the Wnt/beta-catenin signaling pathway. Cancer Epidemiology, 2021, 73, 101972.	1.9	0
17	The impact of health education videos on general publicâ€™s mental health and behavior during COVID-19. Global Health Research and Policy, 2021, 6, 37.	3.6	13
18	Converting health risks into loss of life years - a paradigm shift in clinical risk communication. Aging, 2021, 13, 21513-21525.	3.1	4

#	Article	IF	Citations
19	High NAFLD fibrosis score in non-alcoholic fatty liver disease as a predictor of carotid plaque development: a retrospective cohort study based on regular health check-up data in China. Annals of Medicine, 2021, 53, 1621-1631.	3.8	7
20	Land use mix and leukocyte telomere length in Mexican Americans. Scientific Reports, 2021, 11, 19742.	3.3	1
21	Cohort profile: The National Colorectal Cancer Cohort (NCRCC) study in China. BMJ Open, 2021, 11, e051397.	1.9	2
22	HIF3A DNA methylation, obesity and weight gain, and breast cancer risk among Mexican American women. Obesity Research and Clinical Practice, 2020, 14, 548-553.	1.8	11
23	Genetic associations of T cell cancer immune response-related genes with T cell phenotypes and clinical outcomes of early-stage lung cancer. , 2020, 8, e000336.		9
24	Validation of plasma metabolites associated with breast cancer risk among Mexican Americans. Cancer Epidemiology, 2020, 69, 101826.	1.9	1
25	Household transmission of COVID-19-a systematic review and meta-analysis. Journal of Infection, 2020, 81, 979-997.	3.3	117
26	Perinatal depressive and anxiety symptoms of pregnant women during the coronavirus disease 2019 outbreak in China. American Journal of Obstetrics and Gynecology, 2020, 223, 240.e1-240.e9.	1.3	438
27	Genetic variants in epithelial–mesenchymal transition genes as predictors of clinical outcomes in localized prostate cancer. Carcinogenesis, 2020, 41, 1057-1064.	2.8	0
28	Patterns of racial/ethnic disparities in baseline health-related quality of life and relationship with overall survival in patients with colorectal cancer. Quality of Life Research, 2020, 29, 2977-2986.	3.1	10
29	Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance. Blood Advances, 2020, 4, 2789-2797.	5.2	20
30	Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nature Communications, 2020, 11, 603.	12.8	140
31	A Public Health Perspective on Preventing and Controlling the Spread of Coronavirus Disease 2019. China CDC Weekly, 2020, 2, 237-240.	2.3	0
32	Metabolic hormones and breast cancer risk among Mexican American Women in the Mano a Mano Cohort Study. Scientific Reports, 2019, 9, 9989.	3.3	10
33	Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1228-1237.	2.5	11
34	Sex specific associations in genome wide association analysis of renal cell carcinoma. European Journal of Human Genetics, 2019, 27, 1589-1598.	2.8	27
35	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
36	Elevated Platelet Count Appears to Be Causally Associated with Increased Risk of Lung Cancer: A Mendelian Randomization Analysis. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 935-942.	2.5	21

#	Article	IF	Citations
37	Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer development. Oncotarget, 2019, 10, 1760-1774.	1.8	25
38	Nanotrap-enabled quantification of KRAS-induced peptide hydroxylation in blood for cancer early detection. Nano Research, 2019, 12, 1445-1452.	10.4	5
39	Circulating obesity-driven biomarkers are associated with risk of clear cell renal cell carcinoma: a two-stage, case-control study. Carcinogenesis, 2019, 40, 1191-1197.	2.8	17
40	Cross-Cancer Pleiotropic Associations with Lung Cancer Risk in African Americans. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 715-723.	2.5	11
41	Breast cancer risk in relation to plasma metabolites among Hispanic and African American women. Breast Cancer Research and Treatment, 2019, 176, 687-696.	2.5	13
42	Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients. , 2019, 7, 334.		107
43	The influence of obesity-related factors in the etiology of renal cell carcinomaâ€"A mendelian randomization study. PLoS Medicine, 2019, 16, e1002724.	8.4	59
44	A 5-microRNA signature identified from serum microRNA profiling predicts survival in patients with advanced stage non-small cell lung cancer. Carcinogenesis, 2019, 40, 643-650.	2.8	52
45	Systematic analyses of regulatory variants in DNase I hypersensitive sites identified two novel lung cancer susceptibility loci. Carcinogenesis, 2019, 40, 432-440.	2.8	5
46	Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort. OncoImmunology, 2019, 8, e1483303.	4.6	7
47	Mendelian Randomization and mediation analysis of leukocyte telomere length and risk of lung and head and neck cancers. International Journal of Epidemiology, 2019, 48, 751-766.	1.9	32
48	Sleep duration and risk of cancer in the Mexican American Mano-a-Mano Cohort. Sleep Health, 2019, 5, 78-83.	2.5	16
49	Reply to â€˜Mosaic loss of chromosome Y in leukocytes mattersâ€™. Nature Genetics, 2019, 51, 7-9.	21.4	7
50	Is folic acid safe for nonâ€"muscle-invasive bladder cancer patients? An evidence-based cohort study. American Journal of Clinical Nutrition, 2018, 107, 208-216.	4.7	19
51	Genetic variants in cytokine signaling pathways and clinical outcomes in early-stage lung cancer patients. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2635-2645.e15.	0.8	5
52	Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome. Carcinogenesis, 2018, 39, 752-757.	2.8	18
53	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	6.4	15
54	Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma. European Journal of Cancer, 2018, 92, 20-32.	2.8	21

#	ARTICLE	IF	CITATIONS
55	Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. Carcinogenesis, 2018, 39, 336-346.	2.8	29
56	Cancer risk associated with chronic diseases and disease markers: prospective cohort study. BMJ: British Medical Journal, 2018, 360, k134.	2.3	97
57	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. British Journal of Cancer, 2018, 118, 1419-1424.	6.4	7
58	Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell, 2018, 33, 752-769.e8.	16.8	58
59	The somatic mutation landscape of premalignant colorectal adenoma. Gut, 2018, 67, 1299-1305.	12.1	52
60	Novel genetic variants in the P38MAPK pathway gene <i>ZAK</i> and susceptibility to lung cancer. Molecular Carcinogenesis, 2018, 57, 216-224.	2.7	9
61	Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-Î² Pathway. Gastroenterology, 2018, 154, 195-210.	1.3	105
62	Serum MicroRNAâ€150 Predicts Prognosis for Earlyâ€Stage Nonâ€Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene <i>SRCIN1</i>. Clinical Pharmacology and Therapeutics, 2018, 103, 1061-1073.	4.7	31
63	Prevalence of Aflatoxin-Associated <i>TP53R249S</i> Mutation in Hepatocellular Carcinoma in Hispanics in South Texas. Cancer Prevention Research, 2018, 11, 103-112.	1.5	19
64	Dietary patterns and risk of recurrence and progression in nonâ€muscleâ€invasive bladder cancer. International Journal of Cancer, 2018, 142, 1797-1804.	5.1	23
65	Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer. Cancer, 2018, 124, 785-796.	4.1	52
66	Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. Nature Communications, 2018, 9, 3927.	12.8	43
67	Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine. Cell Death and Differentiation, 2018, 25, 1885-1904.	11.2	31
68	Serum miR-331-3p predicts tumor recurrence in esophageal adenocarcinoma. Scientific Reports, 2018, 8, 14006.	3.3	26
69	Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence. American Journal of Pathology, 2018, 188, 2487-2496.	3.8	34
70	Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process. Oncotarget, 2018, 9, 12868-12878.	1.8	46
71	Socio-demographic, Clinical, and Genetic Determinants of Quality of Life in Lung Cancer Patients. Scientific Reports, 2018, 8, 10640.	3.3	16
72	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	2.5	9

#	Article	IF	Citations
73	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	4.1	3
74	Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nature Communications, 2018, 9, 3221.	12.8	60
75	Genome-wide association study of familial lung cancer. Carcinogenesis, 2018, 39, 1135-1140.	2.8	42
76	Serum microRNAs as predictors of risk for non-muscle invasive bladder cancer. Oncotarget, 2018, 9, 14895-14908.	1.8	11
77	Associations of blood mitochondrial DNA copy number with social-demographics and cancer risk: results from the Mano-A-Mano Mexican American Cohort. Oncotarget, 2018, 9, 25491-25502.	1.8	6
78	Cohort Profile: The Mexican American Mano a Mano Cohort. International Journal of Epidemiology, 2017, 46, e3-e3.	1.9	28
79	Genetic polymorphisms in genes related to risk‐taking behaviours predicting body mass index trajectory among Mexican American adolescents. Pediatric Obesity, 2017, 12, 356-362.	2.8	13
80	D-mannose: a Novel Prognostic Biomarker for Patients with Esophageal Adenocarcinoma. Carcinogenesis, 2017, 38, bgw207.	2.8	19
81	Genetic Variants in Epigenetic Pathways and Risks of Multiple Cancers in the GAME-ON Consortium. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 816-825.	2.5	10
82	Cohort Profile: The Taiwan MJ Cohort: half a million Chinese with repeated health surveillance data. International Journal of Epidemiology, 2017, 46, 1744-1744g.	1.9	70
83	Genetic variants of PTPN2 are associated with lung cancer risk: a re-analysis of eight GWASs in the TRICL-ILCCO consortium. Scientific Reports, 2017, 7, 825.	3.3	10
84	Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncology Letters, 2017, 13, 1949-1957.	1.8	22
85	Associations between language acculturation, age of immigration, and obesity in the Mexican American Mano A Mano cohort. Obesity Research and Clinical Practice, 2017, 11, 544-557.	1.8	10
86	Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncology, The, 2017, 18, 100-111.	10.7	296
87	Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data. Journal of the National Cancer Institute, 2017, 109, .	6.3	42
88	Potential Susceptibility Loci Identified for Renal Cell Carcinoma by Targeting Obesity-Related Genes. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1436-1442.	2.5	2
89	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Nature Communications, 2017, 8, 15724.	12.8	106
90	Prognostic significance of promoter CpG island methylation of obesity‐related genes in patients with nonmetastatic renal cell carcinoma. Cancer, 2017, 123, 3617-3627.	4.1	25

#	Article	IF	Citations
91	Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney International, 2017, 92, 388-396.	5.2	109
92	Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nature Genetics, 2017, 49, 1126-1132.	21.4	472
93	A Serological Biopsy Using Five Stomach-Specific Circulating Biomarkers for Gastric Cancer Risk Assessment: A Multi-Phase Study. American Journal of Gastroenterology, 2017, 112, 704-715.	0.4	81
94	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
95	Functional variants in DCAF4 associated with lung cancer risk in European populations. Carcinogenesis, 2017, 38, 541-551.	2.8	16
96	Plasma MicroRNA signature predicting weight gain among Mexican–American women. Obesity, 2017, 25, 958-964.	3.0	15
97	High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette–Guerin therapy: A long-term survival analysis. OncoImmunology, 2017, 6, e1265719.	4.6	18
98	Associations between genetic variants in mRNA splicing-related genes and risk of lung cancer: a pathway-based analysis from published GWASs. Scientific Reports, 2017, 7, 44634.	3.3	10
99	Measurement of DNA damage in peripheral blood by the γ-H2AX assay as predictor of colorectal cancer risk. DNA Repair, 2017, 53, 24-30.	2.8	15
100	Energy stress-induced lncRNA FILNC1 represses c-Myc-mediated energy metabolism and inhibits renal tumor development. Nature Communications, 2017, 8, 783.	12.8	157
101	Polymorphisms in genes related to epithelial–mesenchymal transition and risk of non-small cell lung cancer. Carcinogenesis, 2017, 38, 1029-1035.	2.8	18
102	Hypertension Susceptibility Loci are Associated with Anthracycline-related Cardiotoxicity in Long-term Childhood Cancer Survivors. Scientific Reports, 2017, 7, 9698.	3.3	23
103	A miR-SNP biomarker linked to an increased lung cancer survival by miRNA-mediated down-regulation of FZD4 expression and Wnt signaling. Scientific Reports, 2017, 7, 9029.	3.3	18
104	Methylation of subtelomeric repeat D4Z4 in peripheral blood leukocytes is associated with biochemical recurrence in localized prostate cancer patients. Carcinogenesis, 2017, 38, 821-826.	2.8	7
105	Genetic variants in telomere–maintenance genes are associated with ovarian cancer risk and outcome. Journal of Cellular and Molecular Medicine, 2017, 21, 510-518.	3.6	13
106	Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. European Urology, 2017, 72, 747-754.	1.9	39
107	Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy. Lung Cancer, 2017, 114, 70-78.	2.0	15
108	Global and targeted serum metabolic profiling of colorectal cancer progression. Cancer, 2017, 123, 4066-4074.	4.1	51

#	Article	IF	Citations
109	Susceptibility loci of <i>CNOT6</i> in the general mRNA degradation pathway and lung cancer riskâ€"A reâ€analysis of eight GWASs. Molecular Carcinogenesis, 2017, 56, 1227-1238.	2.7	10
110	Predictors of health-related quality of life and association with survival may identify colorectal cancer patients at high risk of poor prognosis. Quality of Life Research, 2017, 26, 319-330.	3.1	21
111	Glycemic index, glycemic load and carbohydrate intake in association with risk of renal cell carcinoma. Carcinogenesis, 2017, 38, 1129-1135.	2.8	10
112	Response. Journal of the National Cancer Institute, 2017, 109, .	6.3	0
113	Copy number alterations detected as clonal hematopoiesis of indeterminate potential. Blood Advances, 2017, 1, 1031-1036.	5.2	30
114	Common, germline genetic variations in the novel tumor suppressor <i>BAP1</i> and risk of developing different types of cancer. Oncotarget, 2017, 8, 74936-74946.	1.8	15
115	Epidemiology of Renal Cell Carcinoma. , 2017, , 1-18.		7
116	Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study. PLoS ONE, 2017, 12, e0177875.	2.5	79
117	Social-demographics, health behaviors, and telomere length in the Mexican American Mano a Mano Cohort. Oncotarget, 2017, 8, 96553-96567.	1.8	23
118	Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-GuÃ©rin. Oncotarget, 2017, 8, 88782-88791.	1.8	3
119	LINE-1 methylation in peripheral blood leukocytes and clinical characteristics and prognosis of prostate cancer patients. Oncotarget, 2017, 8, 94020-94027.	1.8	7
120	Association between Genetic Variants in DNA Double-Strand Break Repair Pathways and Risk of Radiation Therapy-Induced Pneumonitis and Esophagitis in Non-Small Cell Lung Cancer. Cancers, 2016, 8, 23.	3.7	13
121	MiRNA-Related Genetic Variations Associated with Radiotherapy-Induced Toxicities in Patients with Locally Advanced Nonâ€"Small Cell Lung Cancer. PLoS ONE, 2016, 11, e0150467.	2.5	7
122	The Role of Physical Activity in Harm Reduction among Betel Quid Chewers from a Prospective Cohort of 419,378 Individuals. PLoS ONE, 2016, 11, e0152246.	2.5	4
123	Mutational Profiles Reveal an Aberrant TGF-Î²-CEA Regulated Pathway in Colon Adenomas. PLoS ONE, 2016, 11, e0153933.	2.5	17
124	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	1.9	71
125	<i>PALB2</i>, <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174
126	Genome-wide association study confirms lung cancer susceptibility loci on chromosomes 5p15 and 15q25 in an African-American population. Lung Cancer, 2016, 98, 33-42.	2.0	49

#	Article	IF	Citations
127	Glycemic Index, Glycemic Load, and Lung Cancer Risk in Non-Hispanic Whites. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 532-539.	2.5	33
128	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	3.8	19
129	Mosaic loss of chromosome Y is associated with common variation near TCL1A. Nature Genetics, 2016, 48, 563-568.	21.4	134
130	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	1.9	111
131	Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes â€" A Meta-Analysis. EBioMedicine, 2016, 11, 219-226.	6.1	40
132	Geneâ€environment interaction of genomeâ€wide association studyâ€identified susceptibility loci and meatâ€cooking mutagens in the etiology of renal cell carcinoma. Cancer, 2016, 122, 108-115.	4.1	24
133	Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance. Carcinogenesis, 2016, 37, 965-971.	2.8	4
134	Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. Nature Communications, 2016, 7, 11843.	12.8	86
135	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nature Communications, 2016, 7, 10933.	12.8	94
136	Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in Taiwan. Scientific Reports, 2016, 6, 36482.	3.3	29
137	Different dietary patterns and reduction of lung cancer risk: A large case-control study in the U.S.. Scientific Reports, 2016, 6, 26760.	3.3	18
138	Lower mitochondrial DNA copy number in peripheral blood leukocytes increases the risk of endometrial cancer. Molecular Carcinogenesis, 2016, 55, 1111-1117.	2.7	19
139	Acculturation and Diabetes Risk in the Mexican American Mano a Mano Cohort. American Journal of Public Health, 2016, 106, 547-549.	2.7	21
140	Novel fluorescence <i>inÂsitu</i> hybridizationâ€based definition of bacille Calmetteâ€GuÃ©rin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. BJU International, 2016, 117, 754-760.	2.5	35
141	Germline Genetic Variants in the Wnt/Î²-Catenin Pathway as Predictors of Colorectal Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 540-546.	2.5	9
142	Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Caseâ€"Control Study. Clinical Cancer Research, 2016, 22, 2074-2082.	7.0	22
143	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. Human Molecular Genetics, 2016, 25, 1663-1676.	2.9	52
144	Cohort Profile: The MD Anderson Cancer Patients and Survivors Cohort (MDA-CPSC). International Journal of Epidemiology, 2016, 45, 713-713f.	1.9	12

#	Article	IF	Citations
145	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Human Molecular Genetics, 2016, 25, 1203-1214.	2.9	38
146	Polymorphisms of the centrosomal gene (*FGFR1OP*) and lung cancer risk: a meta-analysis of 14 463 cases and 44 188 controls. Carcinogenesis, 2016, 37, 280-289.	2.8	7
147	Pathway analysis of bladder cancer genome-wide association study identifies novel pathways involved in bladder cancer development. Genes and Cancer, 2016, 7, 229-239.	1.9	12
148	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	1.8	5
149	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	1.8	13
150	Two-stage induced differentiation of OCT4+/Nanog+ stem-like cells in lung adenocarcinoma. Oncotarget, 2016, 7, 68360-68370.	1.8	20
151	Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes. Oncotarget, 2016, 7, 20486-20495.	1.8	49
152	Heritability of prostate cancer: a tale of rare variants and common single nucleotide polymorphisms. Annals of Translational Medicine, 2016, 4, 206-206.	1.7	16
153	Mobile Phone Use and its Association With Sitting Time and Meeting Physical Activity Recommendations in a Mexican American Cohort. JMIR MHealth and UHealth, 2016, 4, e54.	3.7	3
154	Genetic variations in apoptosis pathway and the risk of ovarian cancer. Oncotarget, 2016, 7, 56737-56745.	1.8	2
155	Clonal Hematopoiesis Increases Risk of Therapy-Related Myeloid Neoplasms. Blood, 2016, 128, 38-38.	1.4	0
156	Genetic variation in the TNF/TRAF2/ASK1/p38 kinase signaling pathway as markers for postoperative pulmonary complications in lung cancer patients. Scientific Reports, 2015, 5, 12068.	3.3	11
157	Acculturation, sociodemographic and lifestyle factors associated with compliance with physical activity recommendations in the Mexican-AmericanMano A Manocohort. BMJ Open, 2015, 5, e008302.	1.9	11
158	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	1.3	22
159	Determination of proline in human serum by a robust LCâ€MS/MS method: application to identification of human metabolites as candidate biomarkers for esophageal cancer early detection and risk stratification. Biomedical Chromatography, 2015, 29, 570-577.	1.7	22
160	Multilevel-analysis identify a cis-expression quantitative trait locus associated with risk of renal cell carcinoma. Oncotarget, 2015, 6, 4097-4109.	1.8	1
161	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	2.5	44
162	The Relationship between Native American Ancestry, Body Mass Index and Diabetes Risk among Mexican-Americans. PLoS ONE, 2015, 10, e0141260.	2.5	24

#	Article	IF	Citations
163	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. Nature Communications, 2015, 6, 5751.	12.8	58
164	Characterization of Large Structural Genetic Mosaicism in Human Autosomes. American Journal of Human Genetics, 2015, 96, 487-497.	6.2	101
165	Identification of Serum Markers of Esophageal Adenocarcinoma by Global and Targeted Metabolic Profiling. Clinical Gastroenterology and Hepatology, 2015, 13, 1730-1737.e9.	4.4	29
166	Biomarkers for Assessing Risk of Cancer. , 2015, , 317-330.e3.		0
167	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
168	ABO blood types and cancer risk—A cohort study of 339,432 subjects in Taiwan. Cancer Epidemiology, 2015, 39, 150-156.	1.9	35
169	Network-Based Integration of GWAS and Gene Expression Identifies a *HOX*-Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	2.5	28
170	Genetic Variants in the Wnt/Î²-Catenin Signaling Pathway as Indicators of Bladder Cancer Risk. Journal of Urology, 2015, 194, 1771-1776.	0.4	32
171	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	1.4	15
172	Depressive Symptoms and Short Telomere Length Are Associated with Increased Mortality in Bladder Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 336-343.	2.5	33
173	Mitochondrial DNA Content as Risk Factor for Bladder Cancer and Its Association with Mitochondrial DNA Polymorphisms. Cancer Prevention Research, 2015, 8, 607-613.	1.5	18
174	The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling. Clinical Cancer Research, 2015, 21, 193-200.	7.0	51
175	Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette–Guerin Instillation for Non-muscle Invasive Bladder Cancer. Annals of Surgical Oncology, 2015, 22, 4104-4110.	1.5	31
176	CYP2A6 reduced activity gene variants confer reduction in lung cancer risk in African American smokers—findings from two independent populations. Carcinogenesis, 2015, 36, 99-103.	2.8	41
177	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	12.8	63
178	Identification of lung cancer histology-specific variants applying Bayesian framework variant prioritization approaches within the TRICL and ILCCO consortia. Carcinogenesis, 2015, 36, 1314-1326.	2.8	15
179	Common variants at the *CHEK2* gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	2.8	24
180	Association of leukocyte telomere length in peripheral blood leukocytes with endometrial cancer risk in Caucasian Americans. Carcinogenesis, 2015, 36, 1327-1332.	2.8	13

#	Article	IF	Citations
181	Mitochondrial DNA copy number in peripheral blood leukocytes and the risk of clear cell renal cell carcinoma. Carcinogenesis, 2015, 36, 249-255.	2.8	25
182	Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer. Carcinogenesis, 2015, 36, 243-248.	2.8	124
183	Genetic variations in base excision repair pathway and risk of bladder cancer: A case–control study in the United States. Molecular Carcinogenesis, 2015, 54, 50-57.	2.7	12
184	Epigenetic analysis of microRNA genes in tumors from surgically resected lung cancer patients and association with survival. Molecular Carcinogenesis, 2015, 54, E45-51.	2.7	18
185	Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer. Oncotarget, 2015, 6, 41988-41996.	1.8	26
186	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
187	Mutagen Sensitivity. , 2015, , 2957-2961.		2
188	Mutagen Sensitivity. , 2015, , 1-4.		0
189	Genetic variants of the Wnt signaling pathway as predictors of recurrence and survival in early-stage non-small cell lung cancer patients. Carcinogenesis, 2014, 35, 1284-1291.	2.8	19
190	High Serum Iron Is Associated with Increased Cancer Risk. Cancer Research, 2014, 74, 6589-6597.	0.9	77
191	A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma. Cancer, 2014, 120, 3635-3641.	4.1	50
192	Genetic and intermediate phenotypic susceptibility markers of gastric cancer in Hispanic Americans: A case–control study. Cancer, 2014, 120, 3040-3048.	4.1	38
193	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
194	Development and validation of risk models and molecular diagnostics to permit personalized management of cancer. Cancer, 2014, 120, 11-19.	4.1	11
195	Genome-wide association study identifies multiple loci associated with bladder cancer risk. Human Molecular Genetics, 2014, 23, 1387-1398.	2.9	137
196	Telomere Length in Peripheral Blood Leukocytes and Lung Cancer Risk: A Large Case–Control Study in Caucasians. Cancer Research, 2014, 74, 2476-2486.	0.9	80
197	A Genome-Wide Association Study of Renal Cell Carcinoma among African Americans. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 209-214.	2.5	20
198	The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease. Cancer Research, 2014, 74, 5808-5818.	0.9	24

#	Article	IF	Citations
199	The Prostate Cancer Susceptibility Variant rs2735839 Near <i>KLK3</i> Gene Is Associated with Aggressive Prostate Cancer and Can Stratify Gleason Score 7 Patients. Clinical Cancer Research, 2014, 20, 5133-5139.	7.0	31
200	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nature Genetics, 2014, 46, 1233-1238.	21.4	147
201	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. American Journal of Human Genetics, 2014, 95, 462-471.	6.2	96
202	Joint Association of Genome-Wide Association Study-Identified Susceptibility Loci and Dietary Patterns in Risk of Renal Cell Carcinoma Among Non-Hispanic Whites. American Journal of Epidemiology, 2014, 180, 499-507.	3.4	18
203	Increased leukocyte mitochondrial DNA copy number is associated with oral premalignant lesions: an epidemiology study. Carcinogenesis, 2014, 35, 1760-1764.	2.8	20
204	Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science, 2014, 346, 256-259.	12.6	834
205	Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nature Genetics, 2014, 46, 736-741.	21.4	360
206	Inflammation-Related Genetic Variations and Survival in Patients With Advanced Nonâ€"Small Cell Lung Cancer Receiving First-Line Chemotherapy. Clinical Pharmacology and Therapeutics, 2014, 96, 360-369.	4.7	16
207	Mutagen Sensitivity as Measured by Induced Chromatid Breakage as a Marker of Cancer Risk. Methods in Molecular Biology, 2014, 1105, 183-192.	0.9	1
208	Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23. Human Molecular Genetics, 2013, 22, 2748-2753.	2.9	59
209	Pathway-Based Serum microRNA Profiling and Survival in Patients with Advanced Stage Nonâ€"Small Cell Lung Cancer. Cancer Research, 2013, 73, 4801-4809.	0.9	80
210	Long telomeres in peripheral blood leukocytes are associated with an increased risk of soft tissue sarcoma. Cancer, 2013, 119, 1885-1891.	4.1	35
211	Genetic variations in regulator of Gâ€‘protein signaling (RGS) confer risk of bladder cancer. Cancer, 2013, 119, 1643-1651.	4.1	17
212	Polymorphisms in the<i>XRCC1</i>gene modify survival of bladder cancer patients treated with chemotherapy. International Journal of Cancer, 2013, 133, 2004-2009.	5.1	27
213	Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nature Genetics, 2013, 45, 680-685.	21.4	154
214	MicroRNA-Related Genetic Variants Associated with Clinical Outcomes in Early-Stage Nonâ€"Small Cell Lung Cancer Patients. Cancer Research, 2013, 73, 1867-1875.	0.9	43
215	Ionizing Radiationâ€"Induced Î³-H2AX Activity in Whole Blood Culture and the Risk of Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 443-451.	2.5	15
216	Association of mitochondrial DNA copy number in peripheral blood leukocytes with risk of esophageal adenocarcinoma. Carcinogenesis, 2013, 34, 2521-2524.	2.8	46

#	Article	IF	Citations
217	Energy Balance, Polymorphisms in the mTOR Pathway, and Renal Cell Carcinoma Risk. Journal of the National Cancer Institute, 2013, 105, 424-432.	6.3	31
218	Genome-Wide Association Study of Genetic Predictors of Overall Survival for Non–Small Cell Lung Cancer in Never Smokers. Cancer Research, 2013, 73, 4028-4038.	0.9	53
219	Â-H2AX level in peripheral blood lymphocytes as a risk predictor for bladder cancer. Carcinogenesis, 2013, 34, 2543-2547.	2.8	22
220	Fine-mapping of the 5p15.33, 6p22.1-p21.31, and 15q25.1 Regions Identifies Functional and Histology-Specific Lung Cancer Susceptibility Loci in African-Americans. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 251-260.	2.5	36
221	Risk Assessment of Esophageal Adenocarcinoma Using Î³-H2AX Assay. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1797-1804.	2.5	15
222	Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer. Human Molecular Genetics, 2013, 22, 825-831.	2.9	54
223	Reduced mitochondrial DNA copy number in peripheral blood leukocytes increases the risk of soft tissue sarcoma. Carcinogenesis, 2013, 34, 1039-1043.	2.8	37
224	Short telomere lengths in peripheral blood leukocytes are associated with an increased risk of oral premalignant lesion and oral squamous cell carcinoma. Cancer, 2013, 119, 4277-4283.	4.1	32
225	Re: Short Telomere Length, Cancer Survival, and Cancer Risk in 47 102 Individuals. Journal of the National Cancer Institute, 2013, 105, 1157-1157.	6.3	12
226	MicroRNA Expression Signatures during Malignant Progression from Barrett's Esophagus to Esophageal Adenocarcinoma. Cancer Prevention Research, 2013, 6, 196-205.	1.5	91
227	Application of Multi-SNP Approaches Bayesian LASSO and AUC-RF to Detect Main Effects of Inflammatory-Gene Variants Associated with Bladder Cancer Risk. PLoS ONE, 2013, 8, e83745.	2.5	21
228	Hepatocellular Carcinoma Risk Prediction Model for the General Population: The Predictive Power of Transaminases. Journal of the National Cancer Institute, 2012, 104, 1599-1611.	6.3	95
229	Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk. Carcinogenesis, 2012, 33, 1699-1706.	2.8	26
230	Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Human Molecular Genetics, 2012, 21, 4980-4995.	2.9	196
231	MicroRNA in the Pathogenesis and Prognosis of Esophageal Cancer. Current Pharmaceutical Design, 2012, 19, 1292-1300.	1.9	89
232	GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis, 2012, 33, 1327-1331.	2.8	46
233	Genetic Variants on 15q25.1, Smoking, and Lung Cancer: An Assessment of Mediation and Interaction. American Journal of Epidemiology, 2012, 175, 1013-1020.	3.4	128
234	Predictors of Survival in Never-Smokers with Non–Small Cell Lung Cancer: A Large-Scale, Two-Phase Genetic Study. Clinical Cancer Research, 2012, 18, 5983-5991.	7.0	13

#	Article	IF	Citations
235	Germline prognostic markers for urinary bladder cancer: Obstacles and opportunities. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 524-532.	1.6	21
236	Association of Polymorphisms in Oxidative Stress Genes with Clinical Outcomes for Bladder Cancer Treated with Bacillus Calmette-Guérin. PLoS ONE, 2012, 7, e38533.	2.5	34
237	A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Human Molecular Genetics, 2012, 21, 456-462.	2.9	81
238	Detectable clonal mosaicism and its relationship to aging and cancer. Nature Genetics, 2012, 44, 651-658.	21.4	519
239	Intake of red meat and heterocyclic amines, metabolic pathway genes and bladder cancer risk. International Journal of Cancer, 2012, 131, 1892-1903.	5.1	26
240	Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. Cancer, 2012, 118, 6188-6198.	4.1	14
241	Genetic Variants in Telomere-Maintenance Genes and Bladder Cancer Risk. PLoS ONE, 2012, 7, e30665.	2.5	18
242	Genetic Variations in the Transforming Growth Factor Beta Pathway as Predictors of Bladder Cancer Risk. PLoS ONE, 2012, 7, e51758.	2.5	20
243	Association study of nicotinic acetylcholine receptor genes identifies a novel lung cancer susceptibility locus near CHRNA1 in African-Americans. Oncotarget, 2012, 3, 1428-1438.	1.8	11
244	Genetic susceptibility to bladder cancer risk and outcome. Personalized Medicine, 2011, 8, 365-374.	1.5	46
245	Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet, The, 2011, 378, 1244-1253.	13.7	1,495
246	Genetic Variations in the Regulator of G-Protein Signaling Genes Are Associated with Survival in Late-Stage Non-Small Cell Lung Cancer. PLoS ONE, 2011, 6, e21120.	2.5	27
247	Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nature Genetics, 2011, 43, 60-65.	21.4	220
248	Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group. BMC Cancer, 2011, 11, 176.	2.6	22
249	A Genome-Wide Association Study Identifies a Locus on Chromosome 14q21 as a Predictor of Leukocyte Telomere Length and as a Marker of Susceptibility for Bladder Cancer. Cancer Prevention Research, 2011, 4, 514-521.	1.5	73
250	A genetic variant near the PMAIP1/Noxa gene is associated with increased bleomycin sensitivity. Human Molecular Genetics, 2011, 20, 820-826.	2.9	11
251	Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer. Carcinogenesis, 2011, 32, 1050-1056.	2.8	32
252	Genome-Wide Association Study of Survival in Non–Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy. Journal of the National Cancer Institute, 2011, 103, 817-825.	6.3	81

#	Article	IF	Citations
253	Novel genetic variants in the chromosome 5p15.33 region associate with lung cancer risk. Carcinogenesis, 2011, 32, 1493-1499.	2.8	59
254	Prospective analysis of DNA damage and repair markers of lung cancer risk from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Carcinogenesis, 2011, 32, 69-73.	2.8	23
255	Variants in Inflammation Genes Are Implicated in Risk of Lung Cancer in Never Smokers Exposed to Second-hand Smoke. Cancer Discovery, 2011, 1, 420-429.	9.4	33
256	A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Human Molecular Genetics, 2011, 20, 4282-4289.	2.9	100
257	Common genetic variants in cell cycle pathway are associated with survival in stage IIIâ€"IV non-small-cell lung cancer. Carcinogenesis, 2011, 32, 1867-1871.	2.8	11
258	Mutagen Sensitivity. , 2011, , 2409-2412.		0
259	The D2 Dopamine Receptor Gene and Nicotine Dependence Among Bladder Cancer Patients and Controls. Behavior Genetics, 2010, 40, 49-58.	2.1	6
260	Genetic variation in MicroRNA genes and risk of oral premalignant lesions. Molecular Carcinogenesis, 2010, 49, 183-189.	2.7	90
261	A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nature Genetics, 2010, 42, 978-984.	21.4	493
262	Genetic Variants in Inflammation-Related Genes Are Associated with Radiation-Induced Toxicity Following Treatment for Non-Small Cell Lung Cancer. PLoS ONE, 2010, 5, e12402.	2.5	91
263	Replication of Lung Cancer Susceptibility Loci at Chromosomes 15q25, 5p15, and 6p21: A Pooled Analysis From the International Lung Cancer Consortium. Journal of the National Cancer Institute, 2010, 102, 959-971.	6.3	174
264	Nicotinic Acetylcholine Receptor Region on Chromosome 15q25 and Lung Cancer Risk Among African Americans: A Caseâ€"Control Study. Journal of the National Cancer Institute, 2010, 102, 1199-1205.	6.3	62
265	Genome-Wide Catalogue of Chromosomal Aberrations in Barrett's Esophagus and Esophageal Adenocarcinoma: A High-Density Single Nucleotide Polymorphism Array Analysis. Cancer Prevention Research, 2010, 3, 1176-1186.	1.5	73
266	Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis, 2010, 31, 1387-1391.	2.8	53
267	Genetic Variations in the Sonic Hedgehog Pathway Affect Clinical Outcomes in Nonâ€"Muscle-Invasive Bladder Cancer. Cancer Prevention Research, 2010, 3, 1235-1245.	1.5	45
268	MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis, 2010, 31, 2118-2123.	2.8	52
269	Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. Carcinogenesis, 2010, 31, 1755-1761.	2.8	20
270	Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis, 2010, 31, 1805-1812.	2.8	120

#	Article	IF	Citations
271	Gamma-radiation sensitivity and polymorphisms in RAD51L1 modulate glioma risk. Carcinogenesis, 2010, 31, 1762-1769.	2.8	11
272	Genetic Variants in MicroRNA Biosynthesis Pathways and Binding Sites Modify Ovarian Cancer Risk, Survival, and Treatment Response. Cancer Research, 2010, 70, 9765-9776.	0.9	118
273	Energy Balance, the PI3K-AKT-mTOR Pathway Genes, and the Risk of Bladder Cancer. Cancer Prevention Research, 2010, 3, 505-517.	1.5	36
274	Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncology, The, 2010, 11, 321-330.	10.7	218
275	Pharmacogenetics of Lung Cancer. , 2010, , 87-106.		0
276	Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis, 2009, 30, 2047-2052.	2.8	85
277	Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated With Chemoradiotherapy. Journal of Clinical Oncology, 2009, 27, 857-871.	1.6	154
278	Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer. Cancer Research, 2009, 69, 6857-6864.	0.9	107
279	Constitutive Short Telomere Length of Chromosome 17p and 12q but not 11q and 2p Is Associated with an Increased Risk for Esophageal Cancer. Cancer Prevention Research, 2009, 2, 459-465.	1.5	69
280	Genetic susceptibility to esophageal cancer: the role of the nucleotide excision repair pathway. Carcinogenesis, 2009, 30, 785-792.	2.8	75
281	Sensitivity to NNKOAc is associated with renal cancer risk. Carcinogenesis, 2009, 30, 706-710.	2.8	35
282	Dietary Intake of Vegetables and Fruits and the Modification Effects of <i>GSTM1</i> and <i>NAT2</i> Genotypes on Bladder Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2090-2097.	2.5	44
283	Family History and Risk of Renal Cell Carcinoma: Results from a Case-Control Study and Systematic Meta-Analysis. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 801-807.	2.5	91
284	Novel Susceptibility Loci for Second Primary Tumors/Recurrence in Head and Neck Cancer Patients: Large-Scale Evaluation of Genetic Variants. Cancer Prevention Research, 2009, 2, 617-624.	1.5	55
285	MicroRNA Expression Signatures in Barrett's Esophagus and Esophageal Adenocarcinoma. Clinical Cancer Research, 2009, 15, 5744-5752.	7.0	120
286	Risk of urinary bladder cancer: a case-control analysis of industry and occupation. BMC Cancer, 2009, 9, 443.	2.6	25
287	Genome‐wide profiling of chromosomal alterations in renal cell carcinoma using high‐density single nucleotide polymorphism arrays. International Journal of Cancer, 2009, 125, 2342-2348.	5.1	80
288	Cyclooxygenase‐2 gene polymorphisms reduce the risk of oral premalignant lesions. Cancer, 2009, 115, 1498-1506.	4.1	22

#	Article	IF	Citations
289	Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications. Cancer and Metastasis Reviews, 2009, 28, 269-280.	5.9	35
290	Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nature Genetics, 2009, 41, 991-995.	21.4	321
291	Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 745-755.	3.3	63
292	Genome-wide association studies in bladder cancer: first results and potential relevance. Current Opinion in Urology, 2009, 19, 540-546.	1.8	22
293	Plasma vitamins E and A and risk of bladder cancer: a case–control analysis. Cancer Causes and Control, 2008, 19, 981-992.	1.8	32
294	Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer, 2008, 112, 2467-2474.	4.1	52
295	Genetic variations in cell‐cycle pathway and the risk of oral premalignant lesions. Cancer, 2008, 113, 2488-2495.	4.1	21
296	Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nature Genetics, 2008, 40, 616-622.	21.4	1,189
297	Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nature Genetics, 2008, 40, 1407-1409.	21.4	510
298	Epidemiology and genetic susceptibility to bladder cancer. BJU International, 2008, 102, 1207-1215.	2.5	59
299	Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. DNA Repair, 2008, 7, 141-148.	2.8	76
300	An Expanded Risk Prediction Model for Lung Cancer. Cancer Prevention Research, 2008, 1, 250-254.	1.5	143
301	Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions. European Journal of Cancer, 2008, 44, 1603-1611.	2.8	27
302	Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncology, The, 2008, 9, 777-785.	10.7	92
303	BPDE Induced Lymphocytic Chromosome 3p Deletions May Predict Renal Cell Carcinoma Risk. Journal of Urology, 2008, 179, 2416-2421.	0.4	22
304	Profiling of Genetic Variations in Inflammation Pathway Genes in Relation to Bladder Cancer Predisposition. Clinical Cancer Research, 2008, 14, 2236-2244.	7.0	49
305	Evaluation of Genetic Variants in MicroRNA-Related Genes and Risk of Bladder Cancer. Cancer Research, 2008, 68, 2530-2537.	0.9	245
306	Case-control analysis of nucleotide excision repair pathway and the risk of renal cell carcinoma. Carcinogenesis, 2008, 29, 2112-2119.	2.8	18

#	Article	IF	Citations
307	Genetic Susceptibility to Renal Cell Carcinoma: The Role of DNA Double-Strand Break Repair Pathway. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2366-2373.	2.5	39
308	The CHRNA5-A3 Region on Chromosome 15q24-25.1 Is a Risk Factor Both for Nicotine Dependence and for Lung Cancer. Journal of the National Cancer Institute, 2008, 100, 1552-1556.	6.3	206
309	Mitochondrial DNA Content: Its Genetic Heritability and Association With Renal Cell Carcinoma. Journal of the National Cancer Institute, 2008, 100, 1104-1112.	6.3	237
310	Familial Aggregation of Common Sequence Variants on 15q24-25.1 in Lung Cancer. Journal of the National Cancer Institute, 2008, 100, 1326-1330.	6.3	141
311	Benzo(<i>a</i>)pyrene Diol Epoxide-Induced Chromosome 9p21 Aberrations Are Associated with Increased Risk of Bladder Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2445-2450.	2.5	12
312	Smoking-related Genomic Signatures in Non–Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 1164-1172.	5.6	39
313	Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenetics and Genomics, 2008, 18, 955-965.	1.5	43
314	Genetic susceptibility to bladder cancer with an emphasis on gene–gene and gene–environmental interactions. Current Opinion in Urology, 2008, 18, 493-498.	1.8	25
315	Strategies to Identify Pharmacogenomic Biomarkers: Candidate Gene, Pathway-Based, and Genome-Wide Approaches. , 2008, , 353-370.		2
316	Pharmacogenetics in Cancer Chemotherapy. , 2008, , 113-128.		1
317	Mutagen Sensitivity and Genetic Variants in Nucleotide Excision Repair Pathway: Genotype-Phenotype Correlation. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2065-2071.	2.5	43
318	Mutagen Sensitivity: A Genetic Predisposition Factor for Cancer: Table 1.. Cancer Research, 2007, 67, 3493-3495.	0.9	75
319	Genetic Variants in Cell Cycle Control Pathway Confer Susceptibility to Lung Cancer. Clinical Cancer Research, 2007, 13, 5974-5981.	7.0	61
320	High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis, 2007, 28, 2160-2165.	2.8	64
321	Projecting Individualized Probabilities of Developing Bladder Cancer in White Individuals. Journal of Clinical Oncology, 2007, 25, 4974-4981.	1.6	67
322	High-Order Interactions among Genetic Variants in DNA Base Excision Repair Pathway Genes and Smoking in Bladder Cancer Susceptibility. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 84-91.	2.5	87
323	Nucleotide Excision Repair Pathway Genes and Oral Premalignant Lesions. Clinical Cancer Research, 2007, 13, 3753-3758.	7.0	55
324	Myeloperoxidase G-463A polymorphism and lung cancer: A HuGE Genetic Susceptibility to Environmental Carcinogens pooled analysis. Genetics in Medicine, 2007, 9, 67-73.	2.4	47

#	Article	IF	Citations
325	A Risk Model for Prediction of Lung Cancer. Journal of the National Cancer Institute, 2007, 99, 715-726.	6.3	362
326	Telomere Dysfunction in Peripheral Lymphocytes as a Potential Predisposition Factor for Renal Cancer. Journal of Urology, 2007, 178, 1492-1496.	0.4	74
327	Differential Induction in Telomerase Activity among Bladder Cancer Patients and Controls on Î³-Radiation. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 606-609.	2.5	10
328	Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and bladder cancer risk. International Journal of Cancer, 2007, 120, 2208-2213.	5.1	82
329	Interplay between mutagen sensitivity and epidemiological factors in modulatinglung cancer risk. International Journal of Cancer, 2007, 120, 2687-2695.	5.1	27
330	ATM sequence variants associate with susceptibility to non-small cell lung cancer. International Journal of Cancer, 2007, 121, 2254-2259.	5.1	29
331	Irradiation-induced telomerase activity and the risk of lung cancer. Cancer, 2007, 109, 1157-1163.	4.1	2
332	Risk assessment of renal cell carcinoma using alkaline comet assay. Cancer, 2007, 110, 282-288.	4.1	14
333	Urinary tract diseases and bladder cancer risk: a case–control study. Cancer Causes and Control, 2007, 18, 839-845.	1.8	28
334	Genetic polymorphism in bladder cancer. Frontiers in Bioscience - Landmark, 2007, 12, 192.	3.0	29
335	Bladder Cancer Predisposition: A Multigenic Approach to DNA-Repair and Cell-Cycle–Control Genes. American Journal of Human Genetics, 2006, 78, 464-479.	6.2	249
336	Deficiency of cell cycle checkpoints and DNA repair system predispose individuals to esophageal cancer. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2006, 602, 143-150.	1.0	13
337	Bladder cancer risk as modified by family history and smoking. Cancer, 2006, 107, 705-711.	4.1	34
338	Matrix Metalloproteinase Polymorphisms and Bladder Cancer Risk. Cancer Research, 2006, 66, 11644-11648.	0.9	71
339	Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions. Carcinogenesis, 2006, 27, 2034-2037.	2.8	44
340	Mutagen Sensitivity Has High Heritability: Evidence from a Twin Study. Cancer Research, 2006, 66, 5993-5996.	0.9	78
341	Mutagen Sensitivity and Neoplastic Progression in Patients with Barrett's Esophagus: A Prospective Analysis. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1935-1940.	2.5	32
342	Genetic Variations in Radiation and Chemotherapy Drug Action Pathways Predict Clinical Outcomes in Esophageal Cancer. Journal of Clinical Oncology, 2006, 24, 3789-3798.	1.6	165

#	Article	IF	Citations
343	Personal Permanent Hair Dye Use Is Not Associated with Bladder Cancer Risk: Evidence from a Case-Control Study. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1746-1749.	2.5	38
344	Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer. Carcinogenesis, 2006, 28, 698-703.	2.8	38
345	Joint Effect of Mutagen Sensitivity and Insulin-Like Growth Factors in Predicting the Risk of Developing Secondary Primary Tumors and Tumor Recurrence in Patients with Head and Neck Cancer. Clinical Cancer Research, 2006, 12, 7194-7201.	7.0	17
346	Mutagen-Induced Chromatid Breakage as a Marker of Cancer Risk. , 2005, 291, 059-068.		10
347	Pharmacogenetics in Esophageal Cancer. Seminars in Oncology, 2005, 32, 87-89.	2.2	6
348	Predictors of esophageal cancer risk: Assessment of susceptibility to DNA damage using comet assay. Genes Chromosomes and Cancer, 2005, 44, 415-422.	2.8	26
349	Case-Control Analysis of Dietary Folate and Risk of Bladder Cancer. Nutrition and Cancer, 2005, 53, 144-151.	2.0	39
350	Opposing Effects of Emphysema, Hay Fever, and Select Genetic Variants on Lung Cancer Risk. American Journal of Epidemiology, 2005, 161, 412-422.	3.4	73
351	Nucleotide Excision Repair Gene Polymorphisms and Recurrence after Treatment for Superficial Bladder Cancer. Clinical Cancer Research, 2005, 11, 1408-1415.	7.0	88
352	Roles of tumor suppressor and telomere maintenance genes in cancer and aging—an epidemiological study. Carcinogenesis, 2005, 26, 1741-1747.	2.8	25
353	Polymorphisms in Inflammation Genes and Bladder Cancer: From Initiation to Recurrence, Progression, and Survival. Journal of Clinical Oncology, 2005, 23, 5746-5756.	1.6	138
354	High Mutagen Sensitivity in Peripheral Blood Lymphocytes Predicts Poor Overall and Disease-Specific Survival in Patients with Stage III Non–Small Cell Lung Cancer Treated with Radiotherapy and Chemotherapy. Clinical Cancer Research, 2005, 11, 2894-2898.	7.0	10
355	Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2005, 581, 97-104.	1.7	92
356	Glutathione peroxidase 1 gene polymorphism and risk of recurrence in patients with superficial bladder cancer. Urology, 2005, 66, 769-774.	1.0	45
357	Cell cycle checkpoints, DNA damage/repair, and lung cancer risk. Cancer Research, 2005, 65, 349-57.	0.9	31
358	Dietary Carotenoids and Genetic Instability Modify Bladder Cancer Risk. Journal of Nutrition, 2004, 134, 3362-3369.	2.9	37
359	Serum Levels of Insulin Growth Factor (IGF-I) and IGF-Binding Protein Predict Risk of Second Primary Tumors in Patients with Head and Neck Cancer. Clinical Cancer Research, 2004, 10, 3988-3995.	7.0	72
360	Genetic susceptibility to tobacco-related cancer. Oncogene, 2004, 23, 6500-6523.	5.9	146

#	Article	IF	Citations
361	Focus on bladder cancer. Cancer Cell, 2004, 6, 111-116.	16.8	252
362	Benzo[a]pyrene diol epoxide-induced 9p21 aberrations associated with genetic predisposition to bladder cancer. Genes Chromosomes and Cancer, 2004, 41, 330-338.	2.8	10
363	Specific chromosome aberrations in peripheral blood lymphocytes are associated with risk of bladder cancer. Genes Chromosomes and Cancer, 2004, 41, 379-389.	2.8	7
364	Methyl-CpG-binding domain 2. Cancer, 2004, 100, 1853-1858.	4.1	19
365	An Evolutionary Perspective on Single-Nucleotide Polymorphism Screening in Molecular Cancer Epidemiology. Cancer Research, 2004, 64, 2251-2257.	0.9	100
366	Myeloperoxidase Promoter Region Polymorphism and Lung Cancer Risk. , 2003, 75, 121-134.		11
367	Assessment of Insulin-Like Growth Factors and Mutagen Sensitivity as Predictors of Lung Cancer Risk. , 2003, 75, 279-288.		0
368	XRCC3 genetic polymorphism, smoking, and lung carcinoma risk in minority populations. Cancer, 2003, 98, 1701-1706.	4.1	26
369	XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. Carcinogenesis, 2003, 24, 505-509.	2.8	149
370	Sulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: a case-control study. Cancer Letters, 2003, 202, 61-69.	7.2	58
371	An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2003, 536, 131-137.	1.7	78
372	From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair, 2003, 2, 901-908.	2.8	184
373	Telomere Dysfunction: A Potential Cancer Predisposition Factor. Journal of the National Cancer Institute, 2003, 95, 1211-1218.	6.3	436
374	Genetic Instability in Bladder Cancer Assessed by the Comet Assay. Journal of the National Cancer Institute, 2003, 95, 540-547.	6.3	89
375	Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 689-98.	2.5	123
376	Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix. Clinical Cancer Research, 2003, 9, 3356-61.	7.0	30
377	p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. Journal of the National Cancer Institute, 2002, 94, 681-690.	6.3	214
378	Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: a case-control analysis. Lung Cancer, 2002, 35, 137-142.	2.0	94

#	Article	IF	Citations
379	A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer, 2002, 37, 35-40.	2.0	84
380	Modification of lung cancer susceptibility by green tea extract as measured by the comet assay. Cancer Detection and Prevention, 2002, 26, 411-418.	2.1	27
381	Association between asbestos exposure, cigarette smoking, myeloperoxidase (MPO) genotypes, and lung cancer risk. American Journal of Industrial Medicine, 2002, 42, 29-37.	2.1	48
382	Microsomal epoxide hydrolase polymorphisms and lung cancer risk in non-Hispanic whites. Molecular Carcinogenesis, 2002, 33, 99-104.	2.7	35
383	A case-control analysis of lymphocytic chromosome 9 aberrations in lung cancer. International Journal of Cancer, 2002, 102, 536-540.	5.1	7
384	BPDE-induced lymphocytic 3p21.3 aberrations may predict head and neck carcinoma risk. Cancer, 2002, 95, 563-568.	4.1	10
385	Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. Cancer Research, 2002, 62, 2813-8.	0.9	36
386	Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 1413-8.	2.5	32
387	Radiation-induced chromatid breaks as a predictor of breast cancer risk. International Journal of Radiation Oncology Biology Physics, 2001, 49, 533-537.	0.8	39
388	Analysis of aromatic DNA adducts and 7,8-dihydro-8-oxo- 2â€²-deoxyguanosine in lymphocyte DNA from a caseâ€"control study of lung cancer involving minority populations. , 2000, 27, 34-46.		65
389	Genetic variants of myeloperoxidase and lung cancer risk. Carcinogenesis, 2000, 21, 1163-1166.	2.8	85
390	Ethnic differences in poly(ADP-ribose) polymerase pseudogene genotype distribution and association with lung cancer risk. Carcinogenesis, 1999, 20, 1465-1470.	2.8	25
391	Genetic Susceptibility to Tobacco Carcinogenesis. Cancer Investigation, 1999, 17, 645-659.	1.3	55
392	Three Measures of Mutagen Sensitivity in a Cancer-Free Population. Cancer Genetics and Cytogenetics, 1999, 110, 65-69.	1.0	18
393	A parallel study of in vitro sensitivity to benzo[a]pyrene diol epoxide and bleomycin in lung carcinoma cases and controls. Cancer, 1998, 83, 1118-1127.	4.1	67
394	Chromosome 5 aberrations and genetic predisposition to lung cancer. , 1998, 79, 490-493.		21
395	Benzo[a]pyrene Diol Epoxide and Bleomycin Sensitivity and Susceptibility to Cancer of Upper Aerodigestive Tract. Journal of the National Cancer Institute, 1998, 90, 1393-1399.	6.3	62
396	Case-Control Study of the D2 Dopamine Receptor Gene and Smoking Status in Lung Cancer Patients. Journal of the National Cancer Institute, 1998, 90, 358-363.	6.3	220

#	Article	IF	Citations
397	Lung carcinoma patients with a family history of cancer and lymphocyte primary chromosome 9 aberrations. , 1997, 79, 1527-1532.		4
398	Mutagen sensitivity in humans: A comparison between two nomenclature systems for recording chromatid breaks. Cancer Genetics and Cytogenetics, 1996, 87, 127-132.	1.0	18
399	Mutagen sensitivity as a marker of cancer susceptibility. Journal of Cellular Biochemistry, 1996, 63, 80-84.	2.6	17
400	Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis, 1995, 16, 2205-2208.	2.8	134